Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

NCT05754502 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT05754502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05754502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
Lead sponsor
Consorzio Oncotech
Phase
Observational
Overall status
Unknown status
Start date
July 27, 2021
Completion date
May 2, 2025
Enrollment
300 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer